Phytochemical Name : Taxus chinensis extract

Properties Information
PhytoCAT-ID PhytoCAT-42
Phytochemical name or plant extracts Taxus chinensis extract
PMID 25981924
Literature evidence CONCLUSION: Together, these results support that administration of PTX in the form of taxane mixtures may become a novel approach to improve the poor bioavailability of PTX.
IUPAC name NA
Phytochemicals’ class or type of plant extracts Extract
Source of phytochemicals or plant Extracts Taxus chinensis
Geographical availability China North-Central, China South-Central, China Southeast
Plant parts NA
Other cancers Breast cancer
Target gene or protein NA
Gene or Protein evidence NA
Target pathways NA
IC50 NA
Potency Oral administration of taxane fractions isolated from Taxus chinensis (containing 17.2% PTX) could achieve remarkably higher blood concentration and systemic exposure of PTX in rats, while the retention of PTX was significantly improved. The TAE had inhibitory effects on the proliferation of tumor cells, and its mechanisms were correlated to inducing the apoptosis of tumor cells.
Cell line/ mice model MCF-7, Rat
Additional information  Taxus chinensis (Pilger) Rehd is widely distributed in China and the northern hemisphere, and the most popular medicinal component isolated from Taxus chinensis is paclitaxel (PTX), which has now become the first-line chemotherapeutic drug for breast cancer and ovarian cancer. Oral administration of pure PTX as a potential anti-cancer agent is compromised by low bioavailability. Further tissue distribution analysis revealed that the penetration of PTX into major tissues was drastically increased compared with that of single PTX. In addition, in MCF-7 cells, the co-existing components in taxane mixtures could strengthen the inhibitory effects of PTX on tumor cell proliferation.
PubChem ID NA
Additional PMIDs 23980363 28868867
Additional sources of information https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:1148780-2
Safety NA